top of page

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...
JMG Logo transparent.png
Executive Spotlights

Beacon Therapeutics Secures $170M in Series B Funding to Accelerate Progress in Ophthalmic Gene Therapy Development

London and Cambridge, MA, July 3, 2024 (PRNewswire) -- Beacon Therapeutics has raised $170 million in Series B funding to advance its ophthalmic gene therapy initiatives, supported by Forbion and other investors. The funding will expedite development of AGTC-501 and other pipeline projects, while new appointments strengthen the company's board governance.


Read full article here.

Recent Posts

See All

Kommentare


Life Science Headlines

© 2024 by Jacobs Management Group, Inc.

​

Privacy Policy

​

bottom of page